Skip to content

Zymeworks ZYME Free cash flow

Free cash flow at other companies

Pfizer logo
PfizerPFE
$2.18B+23.0%
Amgen logo
AmgenAMGN
$1.48B+50.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$25.94M-142%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$37.35M-68.3%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$119.68M-29.0%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$60.94M-146%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Calculated from Zymeworks’s reported figures.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's free cash flow?
Zymeworks (ZYME) reported free cash flow of -$45.93M in Q1 2026.
How has Zymeworks's free cash flow changed year-over-year?
Zymeworks's free cash flow decreased by 1241.9% year-over-year, from -$3.42M to -$45.93M.
What is the long-term trend for Zymeworks's free cash flow?
Over 2 years (2022 to 2025), Zymeworks's free cash flow has grown at a -49.6% compound annual growth rate (CAGR), from $135.96M to -$34.53M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.